Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases

The Use of Kcentra ® in the Reversal of Coagulopathy of Chronic Liver Disease

“…Coagulopathy of chronic liver disease is not the only condition in which Kcentra has been used off label; Kcentra has been described both with and without concurrent FFP for the reversal of target-specific oral anticoagulants, specifically rivaroxaban and apixaban, with evidence limited to animal studies, in vitro studies, and case reports. 16,20,21 Our case series supports the findings of Kwon et al in that 4F-PCC (Kcentra) is an effective and safe alternative to FFP for the treatment of CCLD. Our case series is unique in that we administered Kcentra using an INR-based dosing formula adopted from vitamin K antagonist reversal dosing of Kcentra rather than a fixed dose regardless of INR.…”

“…At best, rFVIIa decreased the amount of blood lost without significant increase in the risk of thrombosis but did not benefit mortality. 21 Select and judicious use of rFVIIa has largely replaced the routine use of this agent. 7,9,19,20,22 A formulation of 4F-PCC other than Kcentra for the treatment of CCLD prior to urgent surgery or invasive procedure was first described by Lorenz et al in 22 patients who were administered an average of 25 units/kg prior to procedures.…”

“…At best, rFVIIa decreased the amount of blood lost without significant increase in the risk of thrombosis but did not benefit mortality. 21 Select and judicious use of rFVIIa has largely replaced the routine use of this agent. 7,9,19,20,22…”

The Use of Kcentra ® in the Reversal of Coagulopathy of Chronic Liver Disease

“…Coagulopathy of chronic liver disease is not the only condition in which Kcentra has been used off label; Kcentra has been described both with and without concurrent FFP for the reversal of target-specific oral anticoagulants, specifically rivaroxaban and apixaban, with evidence limited to animal studies, in vitro studies, and case reports. 16,20,21 Our case series supports the findings of Kwon et al in that 4F-PCC (Kcentra) is an effective and safe alternative to FFP for the treatment of CCLD. Our case series is unique in that we administered Kcentra using an INR-based dosing formula adopted from vitamin K antagonist reversal dosing of Kcentra rather than a fixed dose regardless of INR.…”

“…At best, rFVIIa decreased the amount of blood lost without significant increase in the risk of thrombosis but did not benefit mortality. 21 Select and judicious use of rFVIIa has largely replaced the routine use of this agent. 7,9,19,20,22 A formulation of 4F-PCC other than Kcentra for the treatment of CCLD prior to urgent surgery or invasive procedure was first described by Lorenz et al in 22 patients who were administered an average of 25 units/kg prior to procedures.…”

“…At best, rFVIIa decreased the amount of blood lost without significant increase in the risk of thrombosis but did not benefit mortality. 21 Select and judicious use of rFVIIa has largely replaced the routine use of this agent. 7,9,19,20,22…”

Reporting ‘number needed to treat’ in meta‐analyses: A cross‐sectional study

“…A total of eight systematic reviews, comprising of five Cochrane systematic reviews (8, 10‐13), and three non‐Cochrane systematic reviews/meta‐analyses (14‐16), were identified for this study. Table 4 shows the description of the selected meta‐analyses.…”

Bronchoscopic Intrapulmonary Recombinant Factor VIIa for Diffuse Alveolar Hemorrhage-induced Acute Respiratory Failure in MPO-ANCA Vasculitis: A Case Report

“…rFVIIa was originally developed for treating hemophilic patients. Furthermore, it has been successfully used to treat patients with hemorrhage during major surgery, trauma and hepatic failure [ 7 ]. The rFVIIa-tissue factor complex causes fibrin formation [ 8 ].…”

The Use of Kcentra ® in the Reversal of Coagulopathy of Chronic Liver Disease

“…Coagulopathy of chronic liver disease is not the only condition in which Kcentra has been used off label; Kcentra has been described both with and without concurrent FFP for the reversal of target-specific oral anticoagulants, specifically rivaroxaban and apixaban, with evidence limited to animal studies, in vitro studies, and case reports. 16,20,21 Our case series supports the findings of Kwon et al in that 4F-PCC (Kcentra) is an effective and safe alternative to FFP for the treatment of CCLD. Our case series is unique in that we administered Kcentra using an INR-based dosing formula adopted from vitamin K antagonist reversal dosing of Kcentra rather than a fixed dose regardless of INR.…”

“…At best, rFVIIa decreased the amount of blood lost without significant increase in the risk of thrombosis but did not benefit mortality. 21 Select and judicious use of rFVIIa has largely replaced the routine use of this agent. 7,9,19,20,22 A formulation of 4F-PCC other than Kcentra for the treatment of CCLD prior to urgent surgery or invasive procedure was first described by Lorenz et al in 22 patients who were administered an average of 25 units/kg prior to procedures.…”

“…At best, rFVIIa decreased the amount of blood lost without significant increase in the risk of thrombosis but did not benefit mortality. 21 Select and judicious use of rFVIIa has largely replaced the routine use of this agent. 7,9,19,20,22…”

Reporting ‘number needed to treat’ in meta‐analyses: A cross‐sectional study

“…A total of eight systematic reviews, comprising of five Cochrane systematic reviews (8, 10‐13), and three non‐Cochrane systematic reviews/meta‐analyses (14‐16), were identified for this study. Table 4 shows the description of the selected meta‐analyses.…”

Bronchoscopic Intrapulmonary Recombinant Factor VIIa for Diffuse Alveolar Hemorrhage-induced Acute Respiratory Failure in MPO-ANCA Vasculitis: A Case Report

“…rFVIIa was originally developed for treating hemophilic patients. Furthermore, it has been successfully used to treat patients with hemorrhage during major surgery, trauma and hepatic failure [ 7 ]. The rFVIIa-tissue factor complex causes fibrin formation [ 8 ].…”

The Use of Kcentra ® in the Reversal of Coagulopathy of Chronic Liver Disease

“…Coagulopathy of chronic liver disease is not the only condition in which Kcentra has been used off label; Kcentra has been described both with and without concurrent FFP for the reversal of target-specific oral anticoagulants, specifically rivaroxaban and apixaban, with evidence limited to animal studies, in vitro studies, and case reports. 16,20,21 Our case series supports the findings of Kwon et al in that 4F-PCC (Kcentra) is an effective and safe alternative to FFP for the treatment of CCLD. Our case series is unique in that we administered Kcentra using an INR-based dosing formula adopted from vitamin K antagonist reversal dosing of Kcentra rather than a fixed dose regardless of INR.…”

“…At best, rFVIIa decreased the amount of blood lost without significant increase in the risk of thrombosis but did not benefit mortality. 21 Select and judicious use of rFVIIa has largely replaced the routine use of this agent. 7,9,19,20,22 A formulation of 4F-PCC other than Kcentra for the treatment of CCLD prior to urgent surgery or invasive procedure was first described by Lorenz et al in 22 patients who were administered an average of 25 units/kg prior to procedures.…”

“…At best, rFVIIa decreased the amount of blood lost without significant increase in the risk of thrombosis but did not benefit mortality. 21 Select and judicious use of rFVIIa has largely replaced the routine use of this agent. 7,9,19,20,22…”

Reporting ‘number needed to treat’ in meta‐analyses: A cross‐sectional study

“…A total of eight systematic reviews, comprising of five Cochrane systematic reviews (8, 10‐13), and three non‐Cochrane systematic reviews/meta‐analyses (14‐16), were identified for this study. Table 4 shows the description of the selected meta‐analyses.…”

Bronchoscopic Intrapulmonary Recombinant Factor VIIa for Diffuse Alveolar Hemorrhage-induced Acute Respiratory Failure in MPO-ANCA Vasculitis: A Case Report

“…rFVIIa was originally developed for treating hemophilic patients. Furthermore, it has been successfully used to treat patients with hemorrhage during major surgery, trauma and hepatic failure [ 7 ]. The rFVIIa-tissue factor complex causes fibrin formation [ 8 ].…”